A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects

Apoptosis

Volumn 20, Issue 10, 2015, Pages 1307-1320

  Lao, Xingzhen ^a   Li, Bin ^a   Liu, Meng ^a   Shen, Chen ^a   Yu, Tingting ^a   Gao, Xiangdong ^a   Zheng, Heng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; RGD; Tumor homing

Indexed keywords

CASPASE 9; PROTEIN BAX; THYMOSIN ALPHA1; ANTINEOPLASTIC AGENT; N-END CYSTEINE PEPTIDE TUMOR-HOMING PEPTIDE; OLIGOPEPTIDE; THYMOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CELL ADHESION; CELL ADHESION ASSAY; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CONFORMATION; CYTOLOGY; DRUG EFFECTS; LYMPHOCYTE; MCF 7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; SPLEEN; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HETEROGRAFTS; HUMANS; LYMPHOCYTES; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR CONFORMATION; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; SPLEEN; THYMOSIN;

EID: 84941259365     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1151-z     Document Type: Article

References (51)

1. Goldstein AL, Low TL, McAdoo M, McClure J, Thurman GB et al (1977) Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA 74:725-729
2. Hadden JW (2003) Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 3:1061-1071
3. Leung N (2002) Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 17:409-414
4. Chadwick D, Pido-Lopez J, Pires A, Imami N, Gotch F et al (2003) A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol 134:477-481
5. Goldstein AL, Goldstein AL (2009) From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 9:593-608
6. Danielli R, Fonsatti E, Calabro L, Di Giacomo AM, Maio M (2012) Thymosin alpha1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci 1270:8-12
7. Garaci E, Pica F, Rasi G, Favalli C (2000) Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol 22:1067-1076
8. Garaci E, Pica F, Sinibaldi-Vallebona P, Pierimarchi P, Mastino A et al (2003) Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 3:1145-1150
9. Garaci E, Lopez M, Bonsignore G, Della Giulia M, D'Aprile M et al (1995) Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer 31A:2403-2405
10. Lopez M, Carpano S, Cavaliere R, Di Lauro L, Ameglio F et al (1994) Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 5:741-746
11. Bepler G (1994) Thymosin alpha-1 as adjunct for conventional therapy of malignant-tumors - a review. Cancer Investig 12:491-496
12. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L et al (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510-520
13. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L et al (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031-1035
14. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90
15. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22
16. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106:16157-16162
17. Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T et al (2012) Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 31:3754-3763
18. Lao X, Liu M, Chen J, Zheng H (2013) A tumor-penetrating Peptide modification enhances the antitumor activity of thymosin alpha 1. PLoS One 8:e72242
19. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936-942
20. Wang P, Ballestrem C, Streuli CH (2011) The C terminus of talin links integrins to cell cycle progression. J Cell Biol 195:499-513
21. Wang J, Chen B, Jin N, Xia G, Chen Y et al (2011) The changes of T lymphocytes and cytokines in ICR mice fed with Fe3O4 magnetic nanoparticles. Int J Nanomed 6:605-610
22. Rossi A, Lord JM (2013) Adiponectin inhibits neutrophil apoptosis via activation of AMP kinase, PKB and ERK 1/2 MAP kinase. Apoptosis 18:1469-1480
23. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39-51
24. Shetty J, Klotz KL, Wolkowicz MJ, Flickinger CJ, Herr JC (2007) Radial spoke protein 44 (human meichroacidin) is an axonemal alloantigen of sperm and cilia. Gene 396:93-107
25. Xu HM, Yin R, Chen L, Siraj S, Huang X et al (2008) An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo. Bioconjug Chem 19:1980-1986
26. Yang W, Luo D, Wang S, Wang R, Chen R et al (2008) TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 14:5494-5502
27. Elizondo-Riojas MA, Chamow SM, Tuthill CW, Gorenstein DG, Volk DE (2011) NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun 416:356-361
28. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A et al (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem 53:2215-2226
29. Chen R, Li L, Weng Z (2003) ZDOCK: an initial-stage protein-docking algorithm. Proteins 52:80-87
30. Vintonenko N, Pelaez-Garavito I, Buteau-Lozano H, Toullec A, Lidereau R et al (2011) Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adhes Migr 5:332-343
31. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M et al (2012) Neuropilin-1 expression in cancer and development. J Pathol 226:50-60
32. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V et al (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292:727-730
33. Riedl SJ, Salvesen GS (2007) The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8:405-413
34. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M et al (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489
35. Cepero E, King AM, Coffey LM, Perez RG, Boise LH (2005) Caspase-9 and effector caspases have sequential and distinct effects on mitochondria. Oncogene 24:6354-6366
36. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH (2013) Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol 14:32
37. Wang K, Zhang XF, Liu Y, Liu C, Jiang BH et al (2014) Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35:8735-8747
38. Becker PM, Waltenberger J, Yachechko R, Mirzapoiazova T, Sham JS et al (2005) Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96:1257-1265
39. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C et al (2004) Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103:4232-4239
40. Leichtling KD, Serrate SA, Sztein MB (1990) Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 12:19-29
41. Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C et al (2012) Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 1269:26-33
42. Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G (1998) High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res 18:3571-3578
43. Moody TW, Fagarasan M, Zia F, Cesnjaj M, Goldstein AL (1993) Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res 53:5214-5218
44. Mastino A, Favalli C, Grelli S, Rasi G, Pica F et al (1992) Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 50:493-499
45. Moody TW (2007) Thymosin alpha1 as a chemopreventive agent in lung and breast cancer. Ann N Y Acad Sci 1112:297-304
46. Eliceiri BP, Cheresh DA (2001) Adhesion events in angiogenesis. Curr Opin Cell Biol 13:563-568
47. Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 287:11082-11089
48. Fan YZ, Chang H, Yu Y, Liu J, Wang R (2006) Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides 27:2165-2173
49. Panchal RG (1998) Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 55:247-252
50. Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408-9421
51. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516